Prediction of amikacin dose requirements in neutropenic patients with haematological disease.
This study reports on the use of an easily applied Bayesian forecasting programme (OPT; Clydesoft) to predict amikacin dose requirements in 10 patients with haematological disease and neutropenic fever. OPT-determined dose adjustment achieved therapeutic drug levels for 80% of the peak and 94% of the trough measurements.
Zent
C S
CS
Department of Pharmacology, University of Cape Town.
Allin
R
R
Folb
P I
PI
D000293:Adolescent; D000328:Adult; D000583:Amikacin / Q000008:administration & dosage* / Q000097:blood; D001499:Bayes Theorem; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*
D000583:Amikacin